A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer
Latest Information Update: 17 Sep 2021
At a glance
- Drugs IMNN 001 (Primary) ; Doxorubicin liposomal
- Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms GOG
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 09 Aug 2017 Results published in the Gynecologic Oncology